YN320486 TD-0212 TFA 1073549-11-7

TD-0212 TFA is an orally active dual pharmacologyangiotensin II type 1 receptor (AT1)antagonist and neprilysin (NEP)inhibitor, with a pKi of 8.9 for AT1 and apIC50 of 9.2 for NEP.

YN330065 CY-09 1073612-91-5

CY-09 is a specific NLRP3 inflammasome inhibitor that directly targeted NLRP3 itself。 It is tested against the five major cytochrome P450 enzymes 1A2, 2C9, 2C19, 2D6, and 3A4 with half maximal inhibitory concentrati...

YN320385 Plecanatide acetate 1075732-84-1

Plecanatide acetate, an analogue of Uroguanylin, is an orally activeguanylate cyclase-C (GC-C) receptoragonist. Plecanatide acetate activates GC-C receptors to stimulate cGMP synthesis with an EC50 of 190nM in T84 cells ass...

YN250424 Isoeleutherin 1078723-14-4

Isoeleutherin is a naphthopyran derivative isolated fromE. americana Merr. Et Heynewith anti-fungal, anti-viral, and anti-tumor activities. Isoeleutherin plays an important role in selective modulation of T helper cell-mediated imm...

YN290086 TC-S 7005 1082739-92-1

TC-S 7005 is aPolo-like kinases (Plks)inhibitor with IC50s of 4nM, 24nM and 214nM for Plk2, Plk3, and Plk1, respectively.

YN320492 Z62954982 1090893-12-1

Z62954982 (ZINC08010136) is a potent, selective and  cell-permeableRac1(IC50=12μM) inhibitor that is 4 times more effective than NSC23766 (HY-15723A) (IC50=50μM). Z62954982 disrupts the Rac1/Tiam1 complex and dec...

YN320148 IT1t dihydrochloride 1092776-63-0

IT1t dihydrochloride is a potentCXCR4antagonist; inhibits CXCL12/CXCR4 interaction with an IC50 of 2.1nM.

YN320474 BI-671800 1093108-50-9

BI-671800 (AP-761, Cmpd A) is a highly specific and potent antagonist of chemoattractant receptor-homologous molecule on Th2 cells (DP2/CRTH2) with IC50 of 4.5 nM and 3.7 nM for PGD2 binding to human CRTH2 and...

YN330334 Veledimex 1093130-72-3

Veledimex is an oral activator lig and for a proprietary gene therapy promoter system, and a moderate inhibitor of and substrate forCYP3A4/5.

YN350033 AZD7624 1095004-78-6

AZD7624 is an inhaledp38inhibitor, with potent anti-inflammatory activity.

YN484251 Anti-inflammatory agent 1 1096621-42-9

Anti-inflammatory agent 1 is an anti-inflammatory agent extracted from patent WO 2009003229 A1, example 36.

YN330037 MHP 1104874-94-3

Defensamide (MHP) is an activator of sphingosine kinase (SPHK1) . It can modulate the innate epidermal immune response by potentiating SPHK1 activity and inducing cAMP production.

YN481209 Atorvastatin 3-Deoxyhept-2E... 1105067-93-3

Atorvastatin 3-Deoxyhept-2E-Enoic Acid ((2E)-2,3-Dehydroxy Atorvastatin) is an impurity of Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor and has the ability to effectively decrease blood lipids.

YN330377 Lusutrombopag 1110766-97-6

Lusutrombopag (Mulpleta, S-888711) is an orally bioavailable thrombopoietin (TPO) receptor agonist being developed for chronic liver disease (CLD).

YN250823 Contezolid 1112968-42-9

Contezolid (MRX-I), a new and oraly active oxazolidinone, is an antibiotic in study for complicated skin and soft tissue infections (cSSTI) caused by resistant Gram-positive bacteria. Contezolid (MRX-I) markedly reduces p...

YN330197 IAXO-102 1115270-63-7

IAXO-102 is aTLR4antagonist which negatively regulates TLR4 signalling. It inhibits MAPK and p65 NF-κB phosphorylation and expression of TLR4 dependent proinflammatory protein. IAXO-102 also prevents experiment...

YN380118 Sitravatinib 1123837-84-2

Sitravatinib (MGCD516) is a novel small molecule inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Kit, PDGFRβ, PDGFRα, c-Met, and Axl.

YN450047 ROCK inhibitor-2 1127308-52-4

ROCK inhibitor-2 is a selective dualROCK1 and ROCK2inhibitor with IC50s of 17nM and 2nM, respectively.

YN440317 GDC-0834 Racemate 1133432-46-8

GDC-0834 Racemate is the racemate form of GDC-0834, which is a potent and selective BTK inhibitor with in vitro IC50s of 5.9 and 6.4nM in biochemical and cellular assays, respectively.

YN440316 GDC-0834 1133432-49-1

GDC-0834 is a potent and selectiveBTKinhibitor. GDC-0834 inhibits BTK with an in vitroIC50 of 5.9 and 6.4nM in biochemical and cellular assays, respectively, and in vivoIC50 of 1.1 and 5.6μM in mouse and rat, ...